StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics cash

Cash and short-term investments held at the end of each period.

Keros Therapeutics's cash was $257.61M at Jun 30, 2026. For fiscal 2025 it was $287.42M, down 48.8% from the year before. The highest annual figure on record is $561.38M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$287.42M-48.8%
FY2024Dec 31, 2024$561.38M+68.9%
FY2023Dec 31, 2023$332.36M+19.1%
FY2022Dec 31, 2022$279.05M+20.6%
FY2021Dec 31, 2021$231.37M-13.0%
FY2020Dec 31, 2020$265.99M+3628.0%
FY2019Dec 31, 2019$7.14M-69.5%
FY2018Dec 31, 2018$23.39M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$257.61M-62.7%
Q1 FY2026Mar 31, 2026$281.50M-60.9%
Q4 FY2025Dec 31, 2025$287.42M-48.8%
Q3 FY2025Sep 30, 2025$693.47M+30.7%
Q2 FY2025Jun 30, 2025$690.22M+70.1%
Q1 FY2025Mar 31, 2025$720.54M+62.9%
Q4 FY2024Dec 31, 2024$561.38M+68.9%
Q3 FY2024Sep 30, 2024$530.68M+84.3%
Q2 FY2024Jun 30, 2024$405.86M+26.0%
Q1 FY2024Mar 31, 2024$442.44M+25.9%
Q4 FY2023Dec 31, 2023$332.36M+19.1%
Q3 FY2023Sep 30, 2023$287.89M+20.2%
Q2 FY2023Jun 30, 2023$322.03M+49.3%
Q1 FY2023Mar 31, 2023$351.43M+53.7%
Q4 FY2022Dec 31, 2022$279.05M+20.6%
Q3 FY2022Sep 30, 2022$239.43M+8.2%
Q2 FY2022Jun 30, 2022$215.62M-9.1%
Q1 FY2022Mar 31, 2022$228.59M-10.4%
Q4 FY2021Dec 31, 2021$231.37M-13.0%
Q3 FY2021Sep 30, 2021$221.35M+65.4%
Q2 FY2021Jun 30, 2021$237.11M+63.9%
Q1 FY2021Mar 31, 2021$255.20M+368.1%
Q4 FY2020Dec 31, 2020$265.99M+3628.0%
Q3 FY2020Sep 30, 2020$133.81M+967.7%
Q2 FY2020Jun 30, 2020$144.69M+830.6%
Q1 FY2020Mar 31, 2020$54.52M+162.8%
Q4 FY2019Dec 31, 2019$7.14M-69.5%
Q3 FY2019Sep 30, 2019$12.53M–
Q2 FY2019Jun 30, 2019$15.55M–
Q1 FY2019Mar 31, 2019$20.75M–
Q4 FY2018Dec 31, 2018$23.39M–

More Keros Therapeutics figures

See a number that looks wrong?